Flashback Foreword: Gemcitabine/Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Transitional Cell Carcinoma
Authors: Eric J. Small
Journal: Journal of Clinical Oncology (2023)

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study. August 07, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.00286 Journal of Clinical Oncology - published online before print August 7, 2023 PMID: 37549481 Flashback Foreword: Gemcitabine/Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Transitional Cell Carcinoma Eric J. Small , MD, FASCO1,2xEric J. SmallSearch for articles by this author Show More 1Former Associate Editor, Journal of Clinical Oncology, Alexandria, VA2Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA https://doi.org/10.1200/JCO.23.00286 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 2000, von der Maase et al1 demonstrated the therapeutic equivalence and improved safety profile of gemcitabine plus cisplatin, compared with the time-tested methotrexate, vinblastine, doxorubicin, and cisplatin regimen in patients with locally advanced and metastatic transitional cell bladder cancer. This study identified the first new treatment of bladder cancer in over a decade and presaged a large body of work directed not only at improving efficacy of systemic therapy for advanced bladder cancer but also of making it more broadly available to an older and less fit population.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Gemcitabine/Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin and Cisplatin in Transitional Cell CarcinomaThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Eric J. SmallStock and Other Ownership Interests: Fortis, Harpoon Therapeutics, Teon TherapeuticsHonoraria: Janssen, Johnson and JohnsonConsulting or Advisory Role: Janssen Oncology, Teon Therapeutics, FortisOpen Payments Link: https://openpaymentsdata.cms.gov/physician/660367No other potential conflicts of interest were reported. Companion Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study